Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
Evoke Pharma (NASDAQ: EVOK) announced two upcoming poster presentations featuring Gimoti® nasal spray at the American College of Gastroenterology Annual Scientific Meeting in Philadelphia, October 25-29, 2024. One abstract, Poster P3339, received the ACG's Outstanding Research Award in the Stomach Category and the Presidential Poster Award, an honor given to less than 5% of submitted abstracts. The company will also showcase a new marketing campaign and expanded exhibit booth for GIMOTI at location #361.
Evoke Pharma (NASDAQ: EVOK) ha annunciato due prossime presentazioni di poster che metteranno in evidenza Gimoti® spray nasale durante il Meeting Scientifico Annuale dell'American College of Gastroenterology a Filadelfia, dal 25 al 29 ottobre 2024. Un abstract, Poster P3339, ha ricevuto il Premio per la Ricerca Eccezionale dell'ACG nella Categoria Stomaco e il Premio per il Poster Presidenziale, un riconoscimento assegnato a meno del 5% degli abstract presentati. L'azienda presenterà anche una nuova campagna di marketing e uno stand espositivo ampliato per GIMOTI nella posizione #361.
Evoke Pharma (NASDAQ: EVOK) anunció dos próximas presentaciones de carteles que mostrarán Gimoti® aerosol nasal en la Reunión Científica Anual del Colegio Americano de Gastroenterología en Filadelfia, del 25 al 29 de octubre de 2024. Un resumen, Póster P3339, recibió el Premio a la Investigación Sobresaliente del ACG en la Categoría Estómago y el Premio de Póster Presidencial, un honor otorgado a menos del 5% de los resúmenes presentados. La empresa también presentará una nueva campaña de marketing y un stand ampliado para GIMOTI en la ubicación #361.
Evok Pharma (NASDAQ: EVOK)이 2024년 10월 25일부터 29일까지 필라델피아에서 열리는 미국 위장병학회 연례 과학 회의에서 Gimoti® 비강 스프레이에 관한 두 개의 포스터 발표를 예고했습니다. 하나의 초록인 포스터 P3339는 ACG의 위장 부문 우수 연구상을 수상했으며, 제출된 초록의 5% 미만에게 주어지는 대통령 포스터 상도 수상했습니다. 회사는 또한 GIMOTI에 대한 새로운 마케팅 캠페인과 확장된 전시 부스를 번호 #361에서 선보일 예정입니다.
Evoke Pharma (NASDAQ: EVOK) a annoncé deux présentations de posters à venir présentant Gimoti® spray nasal lors de la réunion scientifique annuelle du Collège américain de gastro-entérologie à Philadelphie, du 25 au 29 octobre 2024. Un résumé, Poster P3339, a reçu le prix de recherche exceptionnelle de l'ACG dans la catégorie estomac et le prix du poster présidentiel, une distinction attribuée à moins de 5 % des résumés soumis. L'entreprise présentera également une nouvelle campagne de marketing et un stand élargi pour GIMOTI au numéro #361.
Evoke Pharma (NASDAQ: EVOK) kündigte zwei bevorstehende Poster-Präsentationen an, die Gimoti® Nasenspray auf dem jährlichen wissenschaftlichen Treffen des American College of Gastroenterology in Philadelphia vom 25. bis 29. Oktober 2024 vorstellen werden. Ein Abstract, Poster P3339, erhielt den ACG Outstanding Research Award in der Kategorie Magen und den Presidential Poster Award, eine Auszeichnung, die weniger als 5% der eingereichten Abstracts erhalten. Das Unternehmen wird auch eine neue Marketingkampagne sowie einen erweiterten Ausstellungsstand für GIMOTI an Standort #361 präsentieren.
- Received prestigious ACG Outstanding Research Award in Stomach Category
- Earned Presidential Poster Award (top 5% of submitted abstracts)
- None.
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, announced upcoming poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, held from October 25-29, 2024.
Evoke will feature two poster presentations highlighting the use of Gimoti® (metoclopramide) nasal spray in patients. Notably, one of these abstracts, Poster P3339, has been honored with the prestigious ACG’s Outstanding Research Award in the Stomach Category for the top abstract across this section of research. It has also been awarded the Presidential Poster Award—a distinction granted to fewer than
Poster Presentation Details:
- Poster Number: P1606
- Session Time: Sunday, October 27, 2024, 3:30 p.m. – 7:00 p.m. ET
- Presenting Authors: Richard McCallum, MD and Michael Cline, DO.
- Poster Number: P3339
- Session Time: Monday, October 28, 2024, 10:30 a.m. – 4:15 p.m. ET
- Presenting Author: David Kunkel, MD
Evoke will also exhibit at ACG, unveiling a newly expanded exhibit booth and introducing our new marketing campaign for GIMOTI. It will be prominently showcased at location #361 in the ACG Exhibit Hall. Please join members of the management and commercial team to learn more about GIMOTI.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
FAQ
When will Evoke Pharma present their Gimoti research at ACG 2024?
What awards did Evoke Pharma (EVOK) receive for their ACG 2024 research?
Where will Evoke Pharma (EVOK) exhibit at the 2024 ACG Meeting?
